The following infographics are based on New Developments in CAR T Treatments Webinar Series, which aired on Tuesday, September 10, at 12 p.m. CDT and featured two presentations from Drs….
CAN-2409 plus valacyclovir and radiation therapy significantly improved DFS in intermediate- to high-risk localized prostate cancer.
Frontline treatment with zanubrutinib continued to improve PFS vs bendamustine plus rituximab at 5 years in patients with treatment-naive CLL/SLL.
With the Oncology Brothers, Uma Borate, MD, discusses how CPX-351 demonstrates superior efficacy over 7+3 chemotherapy in treating acute myeloid leukemia with mutations in measurable…
Second-generation BTK inhibitors were associated with a significantly lower incidence of cardiac adverse effects in B-cell malignancies.
Join us for a virtual session where learners will hear from experts in the field in a didactic & panel case discussion format.
The addition of uproleselan to chemotherapy did not meet the primary OS end point of a phase 3 trial evaluating patients with relapsed/refractory AML.
PURPOSETo assess the efficacy and safety of radiofrequency ablation (RFA) versus stereotactic body radiotherapy (SBRT) in treating recurrent small hepatocellular carcinoma (HCC).METHODSIn this trial, patients…
The essays, reviews, forums, and interviews that readers turned to the most.
Improvements in the 4 hallmarks of myelofibrosis were observed with pelabresib plus ruxolitinib vs placebo plus ruxolitinib in JAK inhibitor-naive disease.
